<DOC>
	<DOCNO>NCT00986414</DOCNO>
	<brief_summary>This phase IIb study design determine safe efficacious dose dose range AFQ056 treatment patient moderate severe Parkinson 's disease L-Dopa induce dyskinesia .</brief_summary>
	<brief_title>Evaluation Efficacy Safety AFQ056 Reducing Moderate Severe L-dopa Induced Dyskinesias Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Outpatients Parkinson 's disease ( PD ) , treat LDopa , experience dyskinesia least three month Surgical treatment PD Cancer within past 5 year ( localized skin cancer prostate cancer effectively treat ) Advanced , severe unstable disease ( PD ) may interfere study outcome evaluation Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>L-dopa</keyword>
	<keyword>Levodopa</keyword>
	<keyword>dyskinesia</keyword>
</DOC>